Zhongxi Bio Completes Pre-A+ Financing Round Led by Qiming Venture Partners

VCBeat has exclusively learned that the innovative life sciences automation technology companyPRCXI Bioinformatics Co., Ltd.(hereinafter referred to as“PRC Xi”) announced the completion of its Pre-A+ financing round, which was exclusively invested by Qiming Venture Partners. The funds raised will be primarily used to expand production capacity, build a comprehensive talent team, and explore new overseas markets.

China’s biotechnology industry is flourishing, and the upgrading of automation tools has become an inevitable trend. However, the majority of the life sciences automation market in China is dominated by a few global giants, resulting in high prices that hinder true affordability and widespread adoption. For the efficient development of China’s biotechnology sector, investment in automation equipment is indispensable.

PRC Xi, founded in 2014, is dedicated to providing comprehensive automation solutions for the life sciences sector. Leveraging its advanced manufacturing capabilities, the company delivers high-performance, cost-effective liquid handling automation solutions to life science laboratories worldwide. Supported by an experienced technical service team, PRC Xi ensures seamless integration of these automation technologies into customers’ existing workflows, thereby empowering them to conduct diverse life science research more efficiently, while also offering comprehensive customized services.

PRC Xi continuously innovates in the field of liquid handling technology, aiming to build an internationally leading platform for liquid handling solutions. It now boasts a comprehensive portfolio of liquid handling products that can easily meet customers’ diverse pipetting needs. From basic liquid transfer to complex sample preparation, PRC Xi’s product portfolio and highly customized solutions enable customers to address these tasks with ease. Through its product lines, PRC Xi helps customers enhance liquid handling precision, reduce manual intervention, and improve production efficiency, thereby effectively lowering operational costs.

PRC Xi's products and services have coveredLife sciences, molecular breeding, biopharmaceuticals, medical diagnostics, food safety, and environmental science, comprehensively supporting customers’ research and industrial needs.

PRC Xi specializes in the manufacturing processes of precision equipment and consumables, adhering to a philosophy of independent production to enhance the efficiency of large-scale manufacturing and reduce operational costs. Through continuous innovation and standardization of its product lines, PRC Xi ensures that every piece of equipment and consumable maintains high stability while achieving optimized cost control.

In 2023, Roche Diagnostics partnered with PRC Xi to co-develop “PRO 384,” an innovative fully automated sample pre-processing system. This system is designed to enhance laboratory workflow efficiency, ensure standardized and automated sample handling, and maximize the accuracy and reliability of testing. Through this collaboration, both parties are jointly promoting the widespread adoption of automation technologies in the field of clinical diagnostics.

PRC Xi has lowered the unit cost of equipment through its meticulously constructed production system, passing these savings on to customers as tangible price reductions. This approach reduces the barrier to technology adoption, enabling more customers to easily access and effectively leverage these advanced automation technologies. Consequently, this accelerates the widespread adoption and promotion of life science automation solutions in the field, thereby speeding up the industry’s automation development process.

In November 2023, DNA-Technology, a leading Russian manufacturer of molecular genetics equipment and reagents, visited PRC Xi for exchange and cooperation.

PRC Xi boasts a nationwide technical support team composed of industry experts who possess profound insights and passion for the life sciences sector. Their professional expertise ensures the successful deployment and efficient operation of solutions provided by PRC Xi. The company offers comprehensive service support covering a full spectrum of professional stages, including solution design, equipment installation, operational training, troubleshooting, and regular maintenance and upkeep, thereby ensuring customers receive timely and thorough service guarantees. Through a worry-free product experience, PRC Xi enables customers to conduct R&D experiments and production activities smoothly and efficiently.

Xinsu Tech and PRC Xi Enter into Strategic Partnership

PRC Xi Forms Strategic Partnership with Dr. Li Xu of Huazhong Agricultural University and Heilongjiang Daodao Yintu

PRC Xi Forms Strategic Partnership with Sanya Haiguji Biology, Led by Professor Xia Zhiqiang of Hainan University

Zhu Bin, Founder and CEO of PRC XiHe stated, “The widespread adoption of automation in life sciences is a growing trend, with automated technologies being increasingly applied across the field. Life science research typically involves extensive experimental procedures and data processing; automation helps laboratories improve efficiency, reduce human error, and enable high-throughput experimentation and data analysis. Although advancing automation in life sciences presents significant challenges, PRC Xi has capitalized on this momentum by continuously strengthening its technical service team and striving to lower product costs. All our efforts are directed toward achieving PRC Xi’s shared goal: ‘to ensure that all researchers can benefit from the convenience and efficiency offered by automated workstations.’ This remains PRC Xi’s established mission and vision.”

Chen Kan, Partner at Qiming Venture PartnersIt stated: “Due to high costs and relatively low market awareness, many laboratories still lack the opportunity to utilize liquid handling workstations. PRC Xi possesses industry-leading capabilities in identifying customer needs, as well as in product development, iteration, manufacturing, and services, enabling it to provide comprehensive high-throughput solutions centered on liquid handling workstations for researchers across various fields. The company’s products, characterized by high cost-performance ratios and flexible configuration options, have gained widespread recognition from numerous clients and hold significant potential for broader adoption in basic research institutions in the future. We also believe that PRC Xi has the potential to rapidly grow into an industry leader in the fields of liquid handling workstations and laboratory automation.”

Qiming Venture Partners, established in 2006, has successively set up offices in Shanghai, Beijing, Suzhou, and Hong Kong, China, as well as in Singapore.

Currently, Qiming Venture Partners manages 11 US dollar funds and seven RMB funds, with total assets under management reaching $9.5 billion. Since its establishment, the firm has focused on investing in outstanding early-stage and growth-stage companies in sectors such as Technology and Consumer (T&C) and Healthcare.

To date, Qiming Venture Partners has invested in more than 530 high-growth innovative companies, of which over 200 have either listed on exchanges such as the NYSE, NASDAQ, HKEX, SSE, and SZSE, or exited through mergers and acquisitions. More than 70 of these portfolio companies have become industry-recognized unicorns or super unicorns.